Impact	O
of	O
antibiotic	B:C0003232
de-escalation	O
on	O
clinical	O
outcomes	O
in	O
community	O
-	O
acquired	O
pneumococcal	O
pneumonia	I:C0032300
.	O

Impact	O
of	O
antibiotic	O
de-escalation	B:C3651014
on	O
clinical	O
outcomes	O
in	O
community	O
-	O
acquired	O
pneumococcal	O
pneumonia	I:C0032300
.	O

Impact	O
of	O
antibiotic	O
de-escalation	O
on	O
clinical	O
outcomes	O
in	O
community	O
-	O
acquired	O
pneumococcal	B:C0032300
pneumonia	I:C0032300
.	O

Although	O
antibiotic	B:C0003232
de-escalation	O
is	O
regarded	O
as	O
a	O
measure	O
that	O
reduces	O
selection	O
pressure	O
,	O
adverse	O
drug	I:C0041755
effects	I:C0041755
and	O
costs	O
,	O
evidence	O
supporting	O
this	O
practice	O
in	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
(	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
)	O
is	O
lacking	O
.	O

Although	O
antibiotic	O
de-escalation	B:C3651014
is	O
regarded	O
as	O
a	O
measure	O
that	O
reduces	O
selection	O
pressure	O
,	O
adverse	O
drug	I:C0041755
effects	I:C0041755
and	O
costs	O
,	O
evidence	O
supporting	O
this	O
practice	O
in	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
(	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
)	O
is	O
lacking	O
.	O

Although	O
antibiotic	O
de-escalation	O
is	O
regarded	O
as	O
a	O
measure	O
that	O
reduces	O
selection	O
pressure	O
,	O
adverse	B:C0041755
drug	I:C0041755
effects	I:C0041755
and	O
costs	O
,	O
evidence	O
supporting	O
this	O
practice	O
in	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
(	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
)	O
is	O
lacking	O
.	O

Although	O
antibiotic	O
de-escalation	O
is	O
regarded	O
as	O
a	O
measure	O
that	O
reduces	O
selection	O
pressure	O
,	O
adverse	O
drug	I:C0041755
effects	I:C0041755
and	O
costs	O
,	O
evidence	O
supporting	O
this	O
practice	O
in	O
community	B:C0032300
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
(	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
)	O
is	O
lacking	O
.	O

Although	O
antibiotic	O
de-escalation	O
is	O
regarded	O
as	O
a	O
measure	O
that	O
reduces	O
selection	O
pressure	O
,	O
adverse	O
drug	I:C0041755
effects	I:C0041755
and	O
costs	O
,	O
evidence	O
supporting	O
this	O
practice	O
in	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
(	O
community	B:C0032300
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
)	O
is	O
lacking	O
.	O

We	O
carried	O
out	O
a	O
retrospective	O
analysis	B:C0936012
of	O
prospectively	O
collected	O
data	O
of	O
a	O
cohort	O
of	O
hospitalized	O
adults	O
with	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
.	O

We	O
carried	O
out	O
a	O
retrospective	O
analysis	O
of	O
prospectively	O
collected	O
data	O
of	O
a	O
cohort	B:C0599755
of	O
hospitalized	O
adults	O
with	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
.	O

We	O
carried	O
out	O
a	O
retrospective	O
analysis	O
of	O
prospectively	O
collected	O
data	O
of	O
a	O
cohort	O
of	O
hospitalized	O
adults	O
with	O
community	B:C0032300
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
.	O

Pneumococcal	B:C0032300
aetiology	O
was	O
established	O
in	O
patients	O
with	O
one	O
or	O
more	O
positive	O
cultures	I:C0159125
for	O
Streptococcus	O
pneumoniae	I:C0038410
obtained	O
from	O
blood	O
,	O
sterile	O
fluids	I:C0005889
or	O
sputum	O
,	O
and	O
/	O
or	O
a	O
positive	O
urinary	O
antigen	I:C1319561
test	I:C1319561
.	O

Pneumococcal	O
aetiology	O
was	O
established	O
in	O
patients	O
with	O
one	O
or	O
more	O
positive	B:C0159125
cultures	I:C0159125
for	O
Streptococcus	O
pneumoniae	I:C0038410
obtained	O
from	O
blood	O
,	O
sterile	O
fluids	I:C0005889
or	O
sputum	O
,	O
and	O
/	O
or	O
a	O
positive	O
urinary	O
antigen	I:C1319561
test	I:C1319561
.	O

Pneumococcal	O
aetiology	O
was	O
established	O
in	O
patients	O
with	O
one	O
or	O
more	O
positive	O
cultures	I:C0159125
for	O
Streptococcus	B:C0038410
pneumoniae	I:C0038410
obtained	O
from	O
blood	O
,	O
sterile	O
fluids	I:C0005889
or	O
sputum	O
,	O
and	O
/	O
or	O
a	O
positive	O
urinary	O
antigen	I:C1319561
test	I:C1319561
.	O

Pneumococcal	O
aetiology	O
was	O
established	O
in	O
patients	O
with	O
one	O
or	O
more	O
positive	O
cultures	I:C0159125
for	O
Streptococcus	O
pneumoniae	I:C0038410
obtained	O
from	O
blood	B:C0005767
,	O
sterile	O
fluids	I:C0005889
or	O
sputum	O
,	O
and	O
/	O
or	O
a	O
positive	O
urinary	O
antigen	I:C1319561
test	I:C1319561
.	O

Pneumococcal	O
aetiology	O
was	O
established	O
in	O
patients	O
with	O
one	O
or	O
more	O
positive	O
cultures	I:C0159125
for	O
Streptococcus	O
pneumoniae	I:C0038410
obtained	O
from	O
blood	O
,	O
sterile	B:C0005889
fluids	I:C0005889
or	O
sputum	O
,	O
and	O
/	O
or	O
a	O
positive	O
urinary	O
antigen	I:C1319561
test	I:C1319561
.	O

Pneumococcal	O
aetiology	O
was	O
established	O
in	O
patients	O
with	O
one	O
or	O
more	O
positive	O
cultures	I:C0159125
for	O
Streptococcus	O
pneumoniae	I:C0038410
obtained	O
from	O
blood	O
,	O
sterile	O
fluids	I:C0005889
or	O
sputum	B:C0038056
,	O
and	O
/	O
or	O
a	O
positive	O
urinary	O
antigen	I:C1319561
test	I:C1319561
.	O

Pneumococcal	O
aetiology	O
was	O
established	O
in	O
patients	O
with	O
one	O
or	O
more	O
positive	O
cultures	I:C0159125
for	O
Streptococcus	O
pneumoniae	I:C0038410
obtained	O
from	O
blood	O
,	O
sterile	O
fluids	I:C0005889
or	O
sputum	O
,	O
and	O
/	O
or	O
a	O
positive	B:C1446409
urinary	O
antigen	I:C1319561
test	I:C1319561
.	O

Pneumococcal	O
aetiology	O
was	O
established	O
in	O
patients	O
with	O
one	O
or	O
more	O
positive	O
cultures	I:C0159125
for	O
Streptococcus	O
pneumoniae	I:C0038410
obtained	O
from	O
blood	O
,	O
sterile	O
fluids	I:C0005889
or	O
sputum	O
,	O
and	O
/	O
or	O
a	O
positive	O
urinary	B:C1319561
antigen	I:C1319561
test	I:C1319561
.	O

De-escalation	B:C3651014
therapy	I:C3651014
was	O
considered	O
when	O
the	O
initial	O
antibiotic	O
therapy	I:C0338237
was	O
narrowed	O
to	O
penicillin	O
,	O
amoxicillin	O
or	O
amoxicillin	O
/	I:C0054066
clavulanate	I:C0054066
within	O
the	O
first	O
72	O
h	O
after	O
admission	O
.	O

De-escalation	O
therapy	I:C3651014
was	O
considered	O
when	O
the	O
initial	O
antibiotic	B:C0338237
therapy	I:C0338237
was	O
narrowed	O
to	O
penicillin	O
,	O
amoxicillin	O
or	O
amoxicillin	O
/	I:C0054066
clavulanate	I:C0054066
within	O
the	O
first	O
72	O
h	O
after	O
admission	O
.	O

De-escalation	O
therapy	I:C3651014
was	O
considered	O
when	O
the	O
initial	O
antibiotic	O
therapy	I:C0338237
was	O
narrowed	O
to	O
penicillin	B:C0220892
,	O
amoxicillin	O
or	O
amoxicillin	O
/	I:C0054066
clavulanate	I:C0054066
within	O
the	O
first	O
72	O
h	O
after	O
admission	O
.	O

De-escalation	O
therapy	I:C3651014
was	O
considered	O
when	O
the	O
initial	O
antibiotic	O
therapy	I:C0338237
was	O
narrowed	O
to	O
penicillin	O
,	O
amoxicillin	B:C0002645
or	O
amoxicillin	O
/	I:C0054066
clavulanate	I:C0054066
within	O
the	O
first	O
72	O
h	O
after	O
admission	O
.	O

De-escalation	O
therapy	I:C3651014
was	O
considered	O
when	O
the	O
initial	O
antibiotic	O
therapy	I:C0338237
was	O
narrowed	O
to	O
penicillin	O
,	O
amoxicillin	O
or	O
amoxicillin	B:C0054066
/	I:C0054066
clavulanate	I:C0054066
within	O
the	O
first	O
72	O
h	O
after	O
admission	O
.	O

De-escalation	O
therapy	I:C3651014
was	O
considered	O
when	O
the	O
initial	O
antibiotic	O
therapy	I:C0338237
was	O
narrowed	O
to	O
penicillin	O
,	O
amoxicillin	O
or	O
amoxicillin	O
/	I:C0054066
clavulanate	I:C0054066
within	O
the	O
first	O
72	O
h	O
after	O
admission	B:C0184666
.	O

Adjustment	O
for	O
confounders	O
was	O
performed	O
with	O
multivariate	O
and	O
propensity	O
score	O
analyses	B:C0936012
.	O

Of	O
1410	O
episodes	O
of	O
community	B:C0032300
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
,	O
antibiotic	O
de-escalation	O
within	O
the	O
first	O
72	O
h	O
after	O
admission	O
was	O
performed	O
in	O
166	O
cases	O
.	O

Of	O
1410	O
episodes	O
of	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
,	O
antibiotic	B:C0003232
de-escalation	O
within	O
the	O
first	O
72	O
h	O
after	O
admission	O
was	O
performed	O
in	O
166	O
cases	O
.	O

Of	O
1410	O
episodes	O
of	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
,	O
antibiotic	O
de-escalation	B:C3651014
within	O
the	O
first	O
72	O
h	O
after	O
admission	O
was	O
performed	O
in	O
166	O
cases	O
.	O

Of	O
1410	O
episodes	O
of	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
,	O
antibiotic	O
de-escalation	O
within	O
the	O
first	O
72	O
h	O
after	O
admission	B:C0184666
was	O
performed	O
in	O
166	O
cases	O
.	O

After	O
adjustment	O
,	O
antibiotic	B:C0003232
de-escalation	O
was	O
not	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
mortality	O
(	O
OR	O
=	O
0.83	O
,	O
95	O
%	O
CI	O
=	O
0.24-2.81	O
)	O
,	O
but	O
it	O
was	O
found	O
to	O
be	O
a	O
protective	O
factor	O
for	O
prolonged	O
LOS	O
(	O
above	O
the	O
median	O
)	O
(	O
OR	O
=	O
0.46	O
,	O
95	O
%	O
CI	O
=	O
0.30	O
-	O
0.70	O
)	O
.	O

After	O
adjustment	O
,	O
antibiotic	O
de-escalation	B:C3651014
was	O
not	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
mortality	O
(	O
OR	O
=	O
0.83	O
,	O
95	O
%	O
CI	O
=	O
0.24-2.81	O
)	O
,	O
but	O
it	O
was	O
found	O
to	O
be	O
a	O
protective	O
factor	O
for	O
prolonged	O
LOS	O
(	O
above	O
the	O
median	O
)	O
(	O
OR	O
=	O
0.46	O
,	O
95	O
%	O
CI	O
=	O
0.30	O
-	O
0.70	O
)	O
.	O

Similar	O
results	O
were	O
found	O
in	O
patients	O
classified	O
into	O
high	B:C0332167
-	I:C0332167
risk	I:C0332167
pneumonia	O
severity	O
index	O
classes	O
(	O
IV	O
-	O
V	O
)	O
,	O
those	O
with	O
clinical	O
instability	I:C1444783
and	O
those	O
with	O
bacteraemia	O
.	O

Similar	O
results	O
were	O
found	O
in	O
patients	O
classified	O
into	O
high	O
-	I:C0332167
risk	I:C0332167
pneumonia	B:C0032285
severity	O
index	O
classes	O
(	O
IV	O
-	O
V	O
)	O
,	O
those	O
with	O
clinical	O
instability	I:C1444783
and	O
those	O
with	O
bacteraemia	O
.	O

Similar	O
results	O
were	O
found	O
in	O
patients	O
classified	O
into	O
high	O
-	I:C0332167
risk	I:C0332167
pneumonia	O
severity	O
index	O
classes	O
(	O
IV	O
-	O
V	O
)	O
,	O
those	O
with	O
clinical	B:C1444783
instability	I:C1444783
and	O
those	O
with	O
bacteraemia	O
.	O

Similar	O
results	O
were	O
found	O
in	O
patients	O
classified	O
into	O
high	O
-	I:C0332167
risk	I:C0332167
pneumonia	O
severity	O
index	O
classes	O
(	O
IV	O
-	O
V	O
)	O
,	O
those	O
with	O
clinical	O
instability	I:C1444783
and	O
those	O
with	O
bacteraemia	B:C0004610
.	O

No	O
significant	O
differences	O
were	O
documented	B:C1301725
in	O
adverse	O
drug	I:C0041755
reactions	I:C0041755
or	O
readmission	O
(	O
<	O
30	O
days	O
)	O
.	O

No	O
significant	O
differences	O
were	O
documented	O
in	O
adverse	B:C0041755
drug	I:C0041755
reactions	I:C0041755
or	O
readmission	O
(	O
<	O
30	O
days	O
)	O
.	O

No	O
significant	O
differences	O
were	O
documented	O
in	O
adverse	O
drug	I:C0041755
reactions	I:C0041755
or	O
readmission	B:C0184666
(	O
<	O
30	O
days	O
)	O
.	O

Antibiotic	B:C0003232
de-escalation	O
seems	O
to	O
be	O
safe	O
and	O
effective	O
in	O
reducing	O
the	O
duration	O
of	O
LOS	O
,	O
and	O
did	O
not	O
adversely	O
affect	I:C0879626
outcomes	O
of	O
patients	O
with	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
,	O
even	O
those	O
with	O
bacteraemia	O
and	O
severe	O
disease	I:C0012634
,	O
and	O
those	O
who	O
were	O
clinically	O
unstable	I:C0443343
.	O

Antibiotic	O
de-escalation	B:C3651014
seems	O
to	O
be	O
safe	O
and	O
effective	O
in	O
reducing	O
the	O
duration	O
of	O
LOS	O
,	O
and	O
did	O
not	O
adversely	O
affect	I:C0879626
outcomes	O
of	O
patients	O
with	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
,	O
even	O
those	O
with	O
bacteraemia	O
and	O
severe	O
disease	I:C0012634
,	O
and	O
those	O
who	O
were	O
clinically	O
unstable	I:C0443343
.	O

Antibiotic	O
de-escalation	O
seems	O
to	O
be	O
safe	O
and	O
effective	O
in	O
reducing	O
the	O
duration	O
of	O
LOS	O
,	O
and	O
did	O
not	O
adversely	B:C0879626
affect	I:C0879626
outcomes	O
of	O
patients	O
with	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
,	O
even	O
those	O
with	O
bacteraemia	O
and	O
severe	O
disease	I:C0012634
,	O
and	O
those	O
who	O
were	O
clinically	O
unstable	I:C0443343
.	O

Antibiotic	O
de-escalation	O
seems	O
to	O
be	O
safe	O
and	O
effective	O
in	O
reducing	O
the	O
duration	O
of	O
LOS	O
,	O
and	O
did	O
not	O
adversely	O
affect	I:C0879626
outcomes	O
of	O
patients	O
with	O
community	B:C0032300
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
,	O
even	O
those	O
with	O
bacteraemia	O
and	O
severe	O
disease	I:C0012634
,	O
and	O
those	O
who	O
were	O
clinically	O
unstable	I:C0443343
.	O

Antibiotic	O
de-escalation	O
seems	O
to	O
be	O
safe	O
and	O
effective	O
in	O
reducing	O
the	O
duration	O
of	O
LOS	O
,	O
and	O
did	O
not	O
adversely	O
affect	I:C0879626
outcomes	O
of	O
patients	O
with	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
,	O
even	O
those	O
with	O
bacteraemia	B:C0004610
and	O
severe	O
disease	I:C0012634
,	O
and	O
those	O
who	O
were	O
clinically	O
unstable	I:C0443343
.	O

Antibiotic	O
de-escalation	O
seems	O
to	O
be	O
safe	O
and	O
effective	O
in	O
reducing	O
the	O
duration	O
of	O
LOS	O
,	O
and	O
did	O
not	O
adversely	O
affect	I:C0879626
outcomes	O
of	O
patients	O
with	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
,	O
even	O
those	O
with	O
bacteraemia	O
and	O
severe	B:C0012634
disease	I:C0012634
,	O
and	O
those	O
who	O
were	O
clinically	O
unstable	I:C0443343
.	O

Antibiotic	O
de-escalation	O
seems	O
to	O
be	O
safe	O
and	O
effective	O
in	O
reducing	O
the	O
duration	O
of	O
LOS	O
,	O
and	O
did	O
not	O
adversely	O
affect	I:C0879626
outcomes	O
of	O
patients	O
with	O
community	O
-	I:C0032300
acquired	I:C0032300
pneumococcal	I:C0032300
pneumonia	I:C0032300
,	O
even	O
those	O
with	O
bacteraemia	O
and	O
severe	O
disease	I:C0012634
,	O
and	O
those	O
who	O
were	O
clinically	B:C0443343
unstable	I:C0443343
.	O

